ARS Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(33,940) | $(10,292) |
| Non-cash adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,298 | 3,315 |
| Depreciation and amortization expense | 280 | 11 |
| Accretion on investments, net of amortization | (1,961) | (1,980) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,128) | — |
| Inventories | (8,449) | — |
| Prepaid expenses and other assets | (4,796) | 867 |
| Donation of equipment | — | 30 |
| Accounts payable and accrued liabilities | 4,168 | 1,344 |
| Operating right-of-use assets and lease liabilities, net | (4) | (5) |
| Contract liability | (210) | — |
| Net cash and cash equivalents used in operating activities | (40,742) | (6,710) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments, available-for-sale | (34,345) | (63,430) |
| Maturities of short-term investments, available-for-sale | 63,500 | 55,000 |
| Purchase of property and equipment | (91) | (83) |
| Net cash and cash equivalents provided by (used in) investing activities | 29,064 | (8,513) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of common stock options | 725 | 258 |
| Net cash and cash equivalents provided by financing activities | 725 | 258 |
| Net decrease in cash and cash equivalents | (10,953) | (14,965) |
| Cash and cash equivalents at beginning of period | 50,817 | 70,971 |
| Cash and cash equivalents at end of period | $39,864 | $56,006 |
| Supplemental cash flow information: | ||
| Remeasurement of right-of-use asset and lease liability from lease modification | $93 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.